Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 5 | 13 | +0,88 % | ||
| ROYALTY PHARMA | 3 | - | +1,19 % | ||
| ALNYLAM PHARMACEUTICALS | 1 | 9 | +2,13 % | ||
| ZYMEWORKS | 1 | 5 | +0,50 % | ||
| DAY ONE BIOPHARMACEUTICALS | 1 | 3 | -3,14 % | ||
| KURA ONCOLOGY | 1 | 2 | +1,19 % | ||
| GUARDANT HEALTH | 1 | 2 | +0,71 % | ||
| CASTLE BIOSCIENCES | 1 | 2 | -1,18 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +3,66 % | ||
| BEAM THERAPEUTICS | 1 | - | -1,61 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:36 | Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation | 253 | AFX News | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced its new five-year strategy, 'Alnylam 2030.' The plan is designed to scale the company's operations by achieving leadership... ► Artikel lesen | |
| 02:06 | Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development | 251 | AFX News | PETAH TIKVA (dpa-AFX) - Royalty Pharma plc (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have entered into a funding agreement of up to $500... ► Artikel lesen | |
| 00:38 | Zweite Chance 2026: +100% Kursgewinn damals - kommt jetzt die Wiederholung? | Hotstock Investor | |||
| 00:10 | Zymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2026 | 340 | GlobeNewswire (Europe) | Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone... ► Artikel lesen | |
| So | MESOBLAST LIMITED: Appendix 3Y for Lyn Cobley | 1 | ASX | ||
| So | Royalty Pharma plc: Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo | 2 | GlobeNewswire (USA) | ||
| So | Teva Pharmaceutical Industries Ltd: Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo | 340 | GlobeNewswire (Europe) | Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-'408... ► Artikel lesen | |
| So | Kura Oncology, Inc.: Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones | 3 | GlobeNewswire (USA) | ||
| So | Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | 1 | GlobeNewswire (USA) | ||
| So | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | 5 | GlobeNewswire (USA) | ||
| So | Castle Biosciences, Inc.: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results | 5 | GlobeNewswire (USA) | ||
| So | Curevac: große Bewegung möglich! | Hebelschein-Spekulant | |||
| So | Index-Update: Walmart verdrängt AstraZeneca im Nasdaq 100 | 869 | börsennews.de | Der US-Einzelhandelsgigant Walmart Inc. steigt in den Nasdaq 100 Index auf und ersetzt dort den Pharmakonzern AstraZeneca. Wie der Indexanbieter Nasdaq am Freitag bekannt gab, werden die Änderungen... ► Artikel lesen | |
| So | ANAVEX LIFE SCIENCES CORP kurz vor dem großen Ausbruch | 4 | Maximilian Berger | ||
| Sa | Here's What Analysts Think About Biogen Inc. (BIIB) | 6 | Insider Monkey | ||
| Sa | Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) - Here's Why | 3 | Insider Monkey | ||
| Sa | Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences | 13 | Insider Monkey | ||
| Sa | Benzinga Bulls And Bears: Chevron, Palantir, Aquestive - And Real Estate Stocks Plummet | 17 | Benzinga.com | ||
| Sa | Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20 | 12 | Seeking Alpha | ||
| Sa | Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle | 1.175 | AFX News | LONDON (dpa-AFX) - Nasdaq (NDAQ) announced that Walmart Inc. (WMT) will join the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted Index (NDXE), and the Nasdaq-100 Ex-Tech Sector Index (NDXX).... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .